Search Results - "Combaret, V"

Emergence of new ALK mutations at relapse of neuroblastoma by Schleiermacher, Gudrun, Javanmardi, Niloufar, Bernard, Virginie, Leroy, Quentin, Cappo, Julie, Rio Frio, Thomas, Pierron, Gaelle, Lapouble, Eve, Combaret, Valérie, Speleman, Frank, de Wilde, Bram, Djos, Anna, Ora, Ingrid, Hedborg, Fredrik, Träger, Catarina, Holmqvist, Britt-Marie, Abrahamsson, Jonas, Peuchmaur, Michel, Michon, Jean, Janoueix-Lerosey, Isabelle, Kogner, Per, Delattre, Olivier, Martinsson, Tommy

“…In neuroblastoma, the ALK receptor tyrosine kinase is activated by point mutations. We investigated the potential role of ALK mutations in neuroblastoma clonal…”
Get full text

Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma by Gattolliat, C-H, Thomas, L, Ciafrè, S A, Meurice, G, Le Teuff, G, Job, B, Richon, C, Combaret, V, Dessen, P, Valteau-Couanet, D, May, E, Busson, P, Douc-Rasy, S, Bénard, J

“…Background: Combination of age at diagnosis, stage and MYCN amplification stratifies neuroblastoma into low-risk and high-risk. We aimed to establish whether a…”
Get full text

Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells by Schönherr, C, Ruuth, K, Kamaraj, S, Wang, C-L, Yang, H-L, Combaret, V, Djos, A, Martinsson, T, Christensen, J G, Palmer, R H, Hallberg, B

“…Neuroblastoma is a neural crest-derived embryonal tumour of the postganglionic sympathetic nervous system and a disease with several different chromosomal…”
Get full text

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN -Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group by Ambros, Inge M, Tonini, Gian-Paolo, Pötschger, Ulrike, Gross, Nicole, Mosseri, Véronique, Beiske, Klaus, Berbegall, Ana P, Bénard, Jean, Bown, Nick, Caron, Huib, Combaret, Valérie, Couturier, Jerome, Defferrari, Raffaella, Delattre, Olivier, Jeison, Marta, Kogner, Per, Lunec, John, Marques, Barbara, Martinsson, Tommy, Mazzocco, Katia, Noguera, Rosa, Schleiermacher, Gudrun, Valent, Alexander, Van Roy, Nadine, Villamon, Eva, Janousek, Dasa, Pribill, Ingrid, Glogova, Evgenia, Attiyeh, Edward F, Hogarty, Michael D, Monclair, Tom F, Holmes, Keith, Valteau-Couanet, Dominique, Castel, Victoria, Tweddle, Deborah A, Park, Julie R, Cohn, Sue, Ladenstein, Ruth, Beck-Popovic, Maja, De Bernardi, Bruno, Michon, Jean, Pearson, Andrew D J, Ambros, Peter F

“…For localized, resectable neuroblastoma without amplification, surgery only is recommended even if incomplete. However, it is not known whether the genomic…”
Get full text

The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking by Mazot, P, Cazes, A, Boutterin, M C, Figueiredo, A, Raynal, V, Combaret, V, Hallberg, B, Palmer, R H, Delattre, O, Janoueix-Lerosey, I, Vigny, M

“…Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK), which is transiently expressed during development of the central and peripheral nervous…”
Get full text

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification by Defferrari, R, Mazzocco, K, Ambros, I M, Ambros, P F, Bedwell, C, Beiske, K, Bénard, J, Berbegall, A P, Bown, N, Combaret, V, Couturier, J, Erminio, G, Gambini, C, Garaventa, A, Gross, N, Haupt, R, Kohler, J, Jeison, M, Lunec, J, Marques, B, Martinsson, T, Noguera, R, Parodi, S, Schleiermacher, G, Tweddle, D A, Valent, A, Van Roy, N, Vicha, A, Villamon, E, Tonini, G P

“…Background: The prognostic impact of segmental chromosome alterations (SCAs) in children older than 1 year, diagnosed with localised unresectable neuroblastoma…”
Get full text

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study) by Schleiermacher, G, Michon, J, Ribeiro, A, Pierron, G, Mosseri, V, Rubie, H, Munzer, C, Bénard, J, Auger, N, Combaret, V, Janoueix-Lerosey, I, Pearson, A, Tweddle, D A, Bown, N, Gerrard, M, Wheeler, K, Noguera, R, Villamon, E, Cañete, A, Castel, V, Marques, B, de Lacerda, A, Tonini, G P, Mazzocco, K, Defferrari, R, de Bernardi, B, di Cataldo, A, van Roy, N, Brichard, B, Ladenstein, R, Ambros, I, Ambros, P, Beiske, K, Delattre, O, Couturier, J

“…Background: In neuroblastoma (NB), the presence of segmental chromosome alterations (SCAs) is associated with a higher risk of relapse. Methods: In order to…”
Get full text

Quality Assessment of Genetic Markers Used for Therapy Stratification by Ambros, I.M., Benard, J., Boavida, M., Bown, N., Caron, H., Combaret, V., Couturier, J., Darnfors, C., Delattre, O., Freeman-Edward, J., Gambini, C., Gross, N., Hattinger, C.M., Luegmayr, A., Lunec, J., Martinsson, T., Mazzocco, K., Navarro, S., Noguera, R., O’Neill, S., Pötschger, U., Rumpler, S., Speleman, F., Tonini, G.P., Valent, A., Van Roy, N., Amann, G., De Bernardi, B., Kogner, P., Ladenstein, R., Michon, J., Pearson, A.D.J., Ambros, P.F.

“…Therapy stratification based on genetic markers is becoming increasingly important, which makes commitment to the highest possible reliability of the involved…”
Get full text

Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification by Plantaz, D., Vandesompele, J., Van Roy, N., Łastowska, M., Bown, N., Combaret, V., Favrot, M.C., Delattre, O., Michon, J., Bénard, J., Hartmann, O., Nicholson, J.C., Ross, F.M., Brinkschmidt, C., Laureys, G., Caron, H., Matthay, K.K., Feuerstein, B.G., Speleman, F.

“…We have studied the occurrence and association of 11q deletions with other chromosomal imbalances in Stage 4 neuroblastomas. To this purpose we have performed…”
Get full text

LMCE3 Treatment Strategy: Results in 99 Consecutively Diagnosed Stage 4 Neuroblastomas in Children Older Than 1 Year at Diagnosis by FRAPPAZ, D, MICHON, J, COMBARET, V, FOURQUET, A, PHILIP, T, ZUCKER, J. M, COZE, C, BERGER, C, PLOUVIER, E, LASSET, C, BERNARD, J. L, STEPHAN, J. L, BOUFFET, E, BUCLON, M

“…To tailor postinduction therapy for stage 4 neuroblastoma in children who are older than 1 year at diagnosis according to status after induction. From March…”
Get full text

Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas by Combaret, V, Gross, N, Lasset, C, Frappaz, D, Peruisseau, G, Philip, T, Beck, D, Favrot, M C

“…In contrast to other human tumors, a repression of the cell-surface glycoprotein CD44 on neuroblastoma is a marker of aggressiveness that usually correlates to…”
Get more information

Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model by JOUANNEAU, Emmanuel, ALBERTI, Laurent, NEJJARI, Mimoun, TREILLEUX, Isabelle, VILGRAIN, Isabelle, DUC, Adeline, COMBARET, Valérie, FAVROT, Marie, LEBOULCH, Philippe, BACHELOT, Thomas

“…Patients with metastatic neuroblastoma are rarely curable with currently available therapy, and the search for new treatment options, which include the use of…”
Get full text

CD44 -- A New Prognostic Marker for Neuroblastoma by Favrot, M.C, Combaret, V, Lasset, C

“…To the Editor: CD44 is a cell-surface glycoprotein involved in cell-cell and cell-matrix interactions 1 . CD44 isoforms are expressed during progression and…”
Get full text

372 Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting the dependence receptor TrkC-induced apoptosis by Tauszig-Delamasure, S, Bouzas-Rodriguez, J, Delloye-Bourgeois, C, Cabrera, J.R, Ichim, G, Raquin, M.A, Rousseau, R, Combaret, V, Bénard, J, Mehlen, P

Get full text

Assessment of percutaneous fine needle aspiration cytology as a technique to provide diagnostic and prognostic information in neuroblastoma by Thiesse, P, Hany, M.A, Combaret, V, Ranchère-Vince, D, Bouffet, E, Bergeron, C

“…The International Neuroblastoma Staging System (INSS) criteria for diagnosis requires an unequivocal pathological diagnosis and favours the identification of…”
Get full text

Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1) by Bellini, Angela, Pötschger, Ulrike, Bernard, Virginie, Lapouble, Eve, Baulande, Sylvain, Ambros, Peter F, Auger, Nathalie, Beiske, Klaus, Bernkopf, Marie, Betts, David R, Bhalshankar, Jaydutt, Bown, Nick, de Preter, Katleen, Clément, Nathalie, Combaret, Valérie, Font de Mora, Jaime, George, Sally L, Jiménez, Irene, Jeison, Marta, Marques, Barbara, Martinsson, Tommy, Mazzocco, Katia, Morini, Martina, Mühlethaler-Mottet, Annick, Noguera, Rosa, Pierron, Gaelle, Rossing, Maria, Taschner-Mandl, Sabine, Van Roy, Nadine, Vicha, Ales, Chesler, Louis, Balwierz, Walentyna, Castel, Victoria, Elliott, Martin, Kogner, Per, Laureys, Geneviève, Luksch, Roberto, Malis, Josef, Popovic-Beck, Maja, Ash, Shifra, Delattre, Olivier, Valteau-Couanet, Dominique, Tweddle, Deborah A, Ladenstein, Ruth, Schleiermacher, Gudrun

“…In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied…”
Get full text

Evaluation of CD44 prognostic value in neuroblastoma: Comparison with the other prognostic factors by Combaret, V., Lasset, C., Frappaz, D., Bouvier, R., Thiesse, P., Rebillard, A.-C., Philip, T., Favrot, M.C.

“…CD44 gene products are potential markers of aggressiveness in different tumour models, a result which prompted us to study clinical neuiroblastoma (NB)…”
Get full text

In vitro targeting and specific transfection of human neuroblastoma cells by chCE7 antibody-mediated gene transfer by COLL, J.-L, WAGNER, E, COMBARET, V, METCHLER, K, AMSTUTZ, H, IACONO-DI-CACITO, I, SIMON, N, FAVROT, M. C

“…We developed a new vector for gene targeting of neuroblastoma (NB) cells, based on the utilization o a monoclonal antibody (chCE7) covalently linked to…”
Get full text

Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma by Combaret, V, Gross, N, Lasset, C, Frappaz, D, Beretta-Brognara, C, Philip, T, Beck, D, Favrot, M.C

“…This multicentric analysis of tumours obtained from 140 patients with neuroblastoma confirms that the lack of CD44 expression is a highly significant factor of…”
Get full text

Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin by Merrouche, Y, Negrier, S, Bain, C, Combaret, V, Mercatello, A, Coronel, B, Moskovtchenko, J F, Tolstoshev, P, Moen, R, Philip, T

“…Adoptive immunotherapy with tumor-infiltrating lymphocytes (TIL) and interleukin-2 (IL-2) has been reported to mediate tumor regression in some human cancers…”
Get more information